NSAID (Ketorolac/Ibuprofen) — Competitive Intelligence Brief

NSAID (Ketorolac/Ibuprofen) (NSAID (Ketorolac/Ibuprofen)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-steroidal anti-inflammatory drug (NSAID). Area: Pain Management, Inflammation.

marketed Non-steroidal anti-inflammatory drug (NSAID) COX-1 and COX-2 Pain Management, Inflammation Small molecule

Target snapshot

NSAID (Ketorolac/Ibuprofen) (NSAID (Ketorolac/Ibuprofen)) — Thomas Jefferson University. NSAIDs inhibit cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
NSAID (Ketorolac/Ibuprofen) TARGET	NSAID (Ketorolac/Ibuprofen)	Thomas Jefferson University	marketed	Non-steroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
Cytotec	Misoprostol	Pfizer	marketed	NSAID combined with prostaglandin analog	Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors	1988-01-01
Ropivacaine, Ketorolac and Adrenaline	Ropivacaine, Ketorolac and Adrenaline	University of Aarhus	marketed	Local anesthetic combination with NSAID and vasopressor	Voltage-gated sodium channels (ropivacaine); COX-1 and COX-2 (ketorolac); alpha and beta adrenergic receptors (adrenaline)
Tylenol and Ibuprofen only	Tylenol and Ibuprofen only	The Cooper Health System	marketed	Analgesic/Antipyretic combination (acetaminophen + NSAID)	Prostaglandin synthesis pathway; COX-1 and COX-2 enzymes
Bromfenac Sodium 0.07%	Bromfenac Sodium 0.07%	Retina Research Institute, LLC	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
Topical diclofenac sodium gel	Topical diclofenac sodium gel	Guang'anmen Hospital of China Academy of Chinese Medical Sciences	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2 enzymes
Ketorolac Nasal Spray	Ketorolac Nasal Spray	Hersh, Elliot V., DMD, MS, PhD	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-steroidal anti-inflammatory drug (NSAID) class)

1. Ain Shams University · 1 drug in this class
2. IBSA Institut Biochimique SA · 1 drug in this class
3. Insel Gruppe AG, University Hospital Bern · 1 drug in this class
4. Pfizer · 1 drug in this class
5. Rabin Medical Center · 1 drug in this class
6. Saglik Bilimleri Universitesi Gulhane Tip Fakultesi · 1 drug in this class
7. Shijiazhuang Yiling Pharmaceutical Co. Ltd · 1 drug in this class
8. Takeda · 1 drug in this class
9. Thomas Jefferson University · 1 drug in this class